CA2205091A1 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
CA2205091A1
CA2205091A1 CA002205091A CA2205091A CA2205091A1 CA 2205091 A1 CA2205091 A1 CA 2205091A1 CA 002205091 A CA002205091 A CA 002205091A CA 2205091 A CA2205091 A CA 2205091A CA 2205091 A1 CA2205091 A1 CA 2205091A1
Authority
CA
Canada
Prior art keywords
enzyme
dna
prodrug
cells
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002205091A
Other languages
English (en)
French (fr)
Inventor
Christopher John Taylorson
Hendrikus Johannes Eggelte
Antonio Tarragona-Fiol
Brian Robert Rabin
Francis Thomas Boyle
John Frederick Hennam
David Charles Blakey
Peter Robert Marsham
David William Heaton
David Huw Davies
Anthony Michael Slater
Laurent Francois Andre Hennequin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Biotechnology Ltd
Original Assignee
Zeneca Limited
Christopher John Taylorson
Hendrikus Johannes Eggelte
Antonio Tarragona-Fiol
Brian Robert Rabin
Francis Thomas Boyle
John Frederick Hennam
David Charles Blakey
Peter Robert Marsham
David William Heaton
David Huw Davies
Anthony Michael Slater
Laurent Francois Andre Hennequin
Syngenta Limited
Astrazeneca Uk Limited
London Biotechnology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2205091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Zeneca Limited, Christopher John Taylorson, Hendrikus Johannes Eggelte, Antonio Tarragona-Fiol, Brian Robert Rabin, Francis Thomas Boyle, John Frederick Hennam, David Charles Blakey, Peter Robert Marsham, David William Heaton, David Huw Davies, Anthony Michael Slater, Laurent Francois Andre Hennequin, Syngenta Limited, Astrazeneca Uk Limited, London Biotechnology Limited filed Critical Zeneca Limited
Publication of CA2205091A1 publication Critical patent/CA2205091A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • External Artificial Organs (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
CA002205091A 1994-12-23 1995-12-21 Chemical compounds Abandoned CA2205091A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GB9426192.2 1994-12-23
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
GB9516810.0 1995-08-16

Publications (1)

Publication Number Publication Date
CA2205091A1 true CA2205091A1 (en) 1996-07-04

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205091A Abandoned CA2205091A1 (en) 1994-12-23 1995-12-21 Chemical compounds

Country Status (23)

Country Link
US (1) US5985281A (cs)
EP (1) EP0806964B1 (cs)
JP (1) JP3805365B2 (cs)
KR (1) KR100270650B1 (cs)
CN (1) CN1095677C (cs)
AT (1) ATE222124T1 (cs)
AU (1) AU701916B2 (cs)
BR (1) BR9510490B1 (cs)
CA (1) CA2205091A1 (cs)
CZ (1) CZ195297A3 (cs)
DE (1) DE69527805T2 (cs)
ES (1) ES2181805T3 (cs)
FI (1) FI972683A (cs)
HU (1) HUT77450A (cs)
IL (1) IL116511A0 (cs)
MX (1) MX9704575A (cs)
NO (1) NO972882L (cs)
NZ (1) NZ297529A (cs)
PL (1) PL184031B1 (cs)
RU (1) RU2189251C2 (cs)
SK (1) SK80997A3 (cs)
TR (1) TR199501654A2 (cs)
WO (1) WO1996020011A1 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707689B2 (en) * 1995-08-16 1999-07-15 Astrazeneca Ab Mutated Carboxypeptidase B enzyme conjugated to a tumour targeted antibody for use in Antibody Directed Enzyme Prodrug Therapy
TW406454B (en) 1996-10-10 2000-09-21 Berg Tech Inc High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
CA2344440A1 (en) * 1998-09-18 2000-03-30 Immunomedics, Inc. Antibody directed enzyme prodrug therapy (edept) with glucoronidase
KR20020073127A (ko) * 1999-09-17 2002-09-19 겐자임 트랜스제닉스 코포레이션 형질전환에 의하여 생성된 융합 단백질
AU2003298787A1 (en) * 2002-11-27 2004-06-23 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
DK1945666T3 (da) * 2005-10-21 2013-07-01 Genzyme Corp Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2037954A4 (en) * 2006-06-20 2011-09-14 Janssen Pharmaceutica Nv METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE
WO2008041059A1 (en) 2006-10-03 2008-04-10 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
EP2279003A4 (en) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
ATE123414T1 (de) * 1989-01-23 1995-06-15 Akzo Nobel Nv Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
EP0625205A1 (en) * 1992-01-30 1994-11-23 Genzyme Limited Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
US5985281A (en) 1999-11-16
WO1996020011A1 (en) 1996-07-04
EP0806964B1 (en) 2002-08-14
BR9510490B1 (pt) 2010-10-05
AU4269796A (en) 1996-07-19
FI972683A0 (fi) 1997-06-19
SK80997A3 (en) 1998-02-04
CZ195297A3 (en) 1997-12-17
TR199501654A2 (tr) 1996-07-21
CN1171054A (zh) 1998-01-21
NO972882L (no) 1997-08-19
AU701916B2 (en) 1999-02-11
MX9704575A (es) 1997-10-31
JPH10511547A (ja) 1998-11-10
BR9510490A (pt) 1998-01-13
CN1095677C (zh) 2002-12-11
NZ297529A (en) 1999-07-29
PL184031B1 (pl) 2002-08-30
FI972683A (fi) 1997-06-19
ES2181805T3 (es) 2003-03-01
EP0806964A1 (en) 1997-11-19
ATE222124T1 (de) 2002-08-15
TR199501654A3 (cs) 1996-07-21
HUT77450A (hu) 1998-04-28
NO972882D0 (no) 1997-06-20
JP3805365B2 (ja) 2006-08-02
DE69527805T2 (de) 2003-04-24
IL116511A0 (en) 1996-07-23
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
DE69527805D1 (de) 2002-09-19
RU2189251C2 (ru) 2002-09-20

Similar Documents

Publication Publication Date Title
CA2205091A1 (en) Chemical compounds
AU719513B2 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
EP0979292B1 (en) Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
AU720223B2 (en) Serpin enzyme complex receptor-mediated gene transfer
US8993295B2 (en) Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US6436691B1 (en) Chemical compounds
JP2000504218A (ja) リガンド指令酵素プロドラッグ療法
KR20000010771A (ko) Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued